Bacil Pharma has received approval from the Registrar of Companies, Central Registration Centre (CRC), for the name “Bacil Research & Development Private Limited” for its proposed wholly-owned subsidiary. The approval, dated July 6, 2026, grants the company the right to use the name for a period of 20 days, valid until July 26, 2026. This move marks a step forward in the company's expansion strategy through the establishment of a new subsidiary focused on research and development.

The name reservation was applied for on July 3, 2026, and subsequently approved by Charan Singh, Assistant Registrar of Companies. The approval letter explicitly states that the company cannot commence business or enter into any agreements until a Certificate of Registration is issued by the Registrar of Companies under the provisions of the Companies Act, 2013. The incorporation process is currently under progress, and the company intends to make necessary disclosures upon completion.

Regulatory Compliance and Validity

The approval is subject to specific conditions and timelines. The name availability is valid for 20 days from the date of approval, and the name may be withdrawn if found to be non-compliant with regulations at a later stage. The company must complete the incorporation process within this validity period to secure the name permanently.

The disclosure was made to the BSE Limited pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The intimation was signed by Chaitali Kalpataru Shah, Director of Bacil Pharma, on July 7, 2026.

Key Details of the Name Approval

The company has assured that it will take all necessary steps to complete the incorporation and will inform the exchanges upon receipt of the Certificate of Incorporation.

Bacil Pharma has scheduled a board meeting for July 9, 2026, to consider raising funds by way of a rights issue of equity shares for an aggregate amount of up to ₹50,00,00,000. The proposed fund raising aims to bolster the company's capital base and will be subject to statutory and regulatory approvals under the Companies Act, 2013, and SEBI regulations.

The board will evaluate increasing the authorised share capital to facilitate the rights issue and ensure adequate headroom for the issuance of shares. This move may necessitate the alteration of the capital clause of the Memorandum of Association and other related documents, pending shareholder approval.

Agenda for Board Meeting

The meeting will cover several key proposals, as outlined below:

Regulatory Compliance

The proceedings are in accordance with Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company has also informed that the trading window for dealing in its securities will remain closed for all designated persons and their immediate relatives until 48 hours after the declaration of the board meeting outcome, in compliance with the SEBI (Prohibition of Insider Trading) Regulations, 2015.